Overview
- Elevance reported adjusted Q2 EPS of $7.45, beating expectations, and raised full-year guidance to at least $20.10 GAAP and at least $27.00 adjusted EPS.
- Net income was about $1.45 billion and operating revenue was roughly $49.8 billion, and the company said it will accelerate investments in medical-cost management and Carelon’s value-based services.
- The benefit expense ratio rose to 89.7 percent largely because of higher costs in Medicaid and Medicare-related lines, which helped push operating margin down to about 3.5 percent from 4.9 percent a year earlier.
- Investors focused on the margin squeeze and drove the stock down more than 9 percent in premarket trading despite the earnings beat.
- Insurers have faced elevated medical use since deferred care resumed after the pandemic, keeping benefit ratios above preferred levels and making government-facing businesses a key variable for near-term results as sector peers report next.